Cargando…

MGMT genomic rearrangements contribute to chemotherapy resistance in gliomas

Temozolomide (TMZ) is an oral alkylating agent used for the treatment of glioblastoma and is now becoming a chemotherapeutic option in patients diagnosed with high-risk low-grade gliomas. The O-6-methylguanine-DNA methyltransferase (MGMT) is responsible for the direct repair of the main TMZ-induced...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oldrini, Barbara, Vaquero-Siguero, Nuria, Mu, Quanhua, Kroon, Paula, Zhang, Ying, Galán-Ganga, Marcos, Bao, Zhaoshi, Wang, Zheng, Liu, Hanjie, Sa, Jason K., Zhao, Junfei, Kim, Hoon, Rodriguez-Perales, Sandra, Nam, Do-Hyun, Verhaak, Roel G. W., Rabadan, Raul, Jiang, Tao, Wang, Jiguang, Squatrito, Massimo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7403430/ https://www.ncbi.nlm.nih.gov/pubmed/32753598 http://dx.doi.org/10.1038/s41467-020-17717-0

Ejemplares similares

Do we really know who has an MGMT methylated glioma? Results of an international survey regarding use of MGMT analyses for glioma
por: Malmström, Annika, et al.
Publicado: (2020)

Alu hypomethylation and MGMT hypermethylation in serum as biomarkers of glioma
por: Gong, Mingjie, et al.
Publicado: (2017)

The Significance of MGMT Promoter Methylation Status in Diffuse Glioma
por: Jovanović, Nikola, et al.
Publicado: (2022)

Somatic genome editing with the RCAS-TVA-CRISPR-Cas9 system for precision tumor modeling
por: Oldrini, Barbara, et al.
Publicado: (2018)

MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas and MGMT Silencing to Temozolomide Sensitivity in IDH-Mutant Gliomas
por: ABE, Hideaki, et al.
Publicado: (2018)

Prognostic impact of MGMT promoter methylation and MGMT and CD133 expression in colorectal adenocarcinoma
por: Oliver, Jaime Antonio, et al.
Publicado: (2014)

Concurrent hypermethylation of DNMT1, MGMT and EGFR genes in progression of gliomas
por: Gömöri, Éva, et al.
Publicado: (2012)

Relationship between MGMT gene expression and treatment effectiveness and prognosis in glioma
por: Li, Qiang, et al.
Publicado: (2017)

Immunohistochemical expression of MGMT in gliomas and its role in ascertaining patient survival
por: Butta, Shristi, et al.
Publicado: (2021)

Diagnostic Accuracy of Immunohistochemistry in Detecting MGMT Methylation Status in Patients with Glioma
por: Sahara, Nita, et al.
Publicado: (2021)

MGMT promoter methylation in 1p19q-intact gliomas
por: Kinslow, Connor, et al.
Publicado: (2023)

O(6)-Methylguanine-DNA Methyltransferase (MGMT) mRNA Expression Predicts Outcome in Malignant Glioma Independent of MGMT Promoter Methylation
por: Kreth, Simone, et al.
Publicado: (2011)

Reconstructing the molecular life history of gliomas
por: Barthel, Floris P., et al.
Publicado: (2018)

The possibility of cancer immune editing in gliomas. A critical review
por: Arrieta, Víctor A., et al.
Publicado: (2018)

Glioma: experimental models and reality
por: Lenting, Krissie, et al.
Publicado: (2017)

MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR
por: Håvik, Annette Bentsen, et al.
Publicado: (2012)

Valproic Acid Downregulates the Expression of MGMT and Sensitizes Temozolomide-Resistant Glioma Cells
por: Ryu, Chung Heon, et al.
Publicado: (2012)

miR-221/222 Target the DNA Methyltransferase MGMT in Glioma Cells
por: Quintavalle, Cristina, et al.
Publicado: (2013)

Enhanced MGMT expression contributes to temozolomide resistance in glioma stem-like cells
por: Qiu, Zhi-Kun, et al.
Publicado: (2014)

Ten genes associated with MGMT promoter methylation predict the prognosis of patients with glioma
por: Zhang, Yang, et al.
Publicado: (2019)

An intronic genetic variation of MGMT affects enhancer activity and is associated with glioma susceptibility
por: Huang, Liming, et al.
Publicado: (2018)

Extent and prognostic value of MGMT promotor methylation in glioma WHO grade II
por: Karschnia, Philipp, et al.
Publicado: (2020)

Predicting MGMT Promoter Methylation in Diffuse Gliomas Using Deep Learning with Radiomics
por: Chen, Sixuan, et al.
Publicado: (2022)

The nanoprodrug of polytemozolomide combines with MGMT siRNA to enhance the effect of temozolomide in glioma
por: Xu, Haoyue, et al.
Publicado: (2022)

Experimental study of selective MGMT peptides mimicking TMZ drug resistance in glioma
por: Wu, Yue, et al.
Publicado: (2022)

HDAC4, a prognostic and chromosomal instability marker, refines the predictive value of MGMT promoter methylation
por: Cheng, Wen, et al.
Publicado: (2015)

Association between MGMT Enhancer Methylation and MGMT Promoter Methylation, MGMT Protein Expression, and Overall Survival in Glioblastoma
por: Zappe, Katja, et al.
Publicado: (2023)

Disruption of NF-κB signaling by fluoxetine attenuates MGMT expression in glioma cells
por: Song, Tao, et al.
Publicado: (2015)

MGMT autoantibodies as a potential prediction of recurrence and treatment response biomarker for glioma patients
por: Wu, Haibin, et al.
Publicado: (2019)

O(6)-Methylguanine-DNA Methyltransferase (MGMT): Challenges and New Opportunities in Glioma Chemotherapy
por: Yu, Wei, et al.
Publicado: (2020)

Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide
por: van Nifterik, K A, et al.
Publicado: (2010)

Hypermutagenesis in untreated adult gliomas due to inherited mismatch mutations
por: Sa, Jason K., et al.
Publicado: (2019)

Identification of potentially oncogenic alterations from tumor-only samples reveals Fanconi anemia pathway mutations in bladder carcinomas
por: Madubata, Chioma J, et al.
Publicado: (2017)

High Specificity of Quantitative Methylation-Specific PCR Analysis for MGMT Promoter Hypermethylation Detection in Gliomas
por: Parrella, Paola, et al.
Publicado: (2009)

Treatment of recurrent malignant gliomas with fotemustine monotherapy: impact of dose and correlation with MGMT promoter methylation
por: Fabi, Alessandra, et al.
Publicado: (2009)

An insertion variant of MGMT disrupts a STAT1 binding site and confers susceptibility to glioma
por: Huang, Liming, et al.
Publicado: (2021)

Modeling Colorectal Cancer Progression Reveals Niche-Dependent Clonal Selection
por: Vaquero-Siguero, Nuria, et al.
Publicado: (2022)

Deciphering Brain Complexity Using Single-cell Sequencing
por: Mu, Quanhua, et al.
Publicado: (2019)

Comprehensive Analysis of MGMT Promoter Methylation: Correlation with MGMT Expression and Clinical Response in GBM
por: Shah, Nameeta, et al.
Publicado: (2011)

A ”Clickable” Probe for Active MGMT in Glioblastoma Demonstrates Two Discrete Populations of MGMT
por: Raghavan, Sudhir, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_pja1iioagq1b42deadha3d2jj4